We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
- Authors
Morrell, Louise M.; Bach, Ardalan; Richman, Stephen P.; Goodman, Phyllis; Fleming, Thomas R.; Macdonald, John S.; Morrell, L M; Bach, A; Richman, S P; Goodman, P; Fleming, T R; MacDonald, J S
- Abstract
Adenocarcinoma of the pancreas is a highly lethal malignancy and chemotherapy has had little impact on the natural history of this disease. PALA, used to potentiate 5-fluorouracil (5-FU), has been shown to have synergy in vivo and in vitro. Twenty-seven patients were treated with an intravenous push dose of PALA (250 mg/m2) followed 24 hours later with a 24-hour infusion of 5-FU (2600 mg/m2). This regimen was repeated weekly. There was one partial response of 21 eligible patients with an estimated response rate of 5%. Toxicity was severe with one toxic death and four patients experiencing Grade 4 toxicity. 5-Fluorouracil and PALA, given in the schedule described, do not appear to be effective against adenocarcinoma of the pancreas.
- Publication
Cancer (0008543X), 1991, Vol 67, Issue 2, p363
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19910115)67:2<363::AID-CNCR2820670208>3.0.CO;2-H